Assessment of efficacy of Venetoclax and hypomethylating agent (HMA) combination therapy in treatment naive and relapsed/refractory Acute Myeloid Leukemia patients
Latest Information Update: 17 Dec 2020
At a glance
- Drugs Azacitidine (Primary) ; Decitabine (Primary) ; Venetoclax (Primary)
- Indications Acute myeloid leukaemia
- Focus Therapeutic Use
- 17 Dec 2020 New trial record
- 01 Dec 2020 Results published in the American Journal of Hematology